ARTICLE | Clinical News
MDX-010 regulatory update
October 11, 2004 7:00 AM UTC
FDA granted Fast Track designation to MDX-010 in combination with MDX-1379 to treat previously treated, unresectable stage III and IV metastatic melanoma. MDX-1379 is a gp100 melanoma peptide vaccine...